Victoria Parker
AstraZeneca (United Kingdom)(GB)University of Central Florida(US)AstraZeneca (Spain)(ES)
Publications by Year
Research Areas
Diabetes Treatment and Management, Vascular Malformations and Hemangiomas, Metabolism, Diabetes, and Cancer, Diet and metabolism studies, Pharmacology and Obesity Treatment
Most-Cited Works
- → PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation(2014)553 cited
- → Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy(2018)280 cited
- → Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies(2016)262 cited
- → Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans(2016)185 cited
- → Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum(2018)155 cited
- → X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic axonemal dynein assembly factor PIH1D3(2017)151 cited